With the demonstration that Evofem Biosciences Inc.’s vaginal gel Amphora was able to prevent infection with chlamydia and gonorrhea in a Phase II trial, the company is hopeful that it can add a claim of preventing sexually transmitted infections to a product it is initially marketing for preventing pregnancy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?